Loading
A phase 2/3 trial of cisplatin in pancreatic cancer, run by Fudan University, now recruiting.
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency is a phase 2/3, interventional study registered as NCT06095141 by Fudan University, with a registry enrolment figure of 30 participants, started 2023-12-01 and due to reach its primary completion in 2025-10-31. Interventions recorded: Cisplatin. Conditions listed: Pancreatic Adenocarcinoma; Homologous Recombination Deficiency. Primary outcome: progression-free survival, PFS. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed advanced pancreas adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Platinum agents, Cisplatin and the tag pancreatic-deep-dive.
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Platinum agents and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Platinum agents, Cisplatin and the tag pancreatic-deep-dive.
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Platinum agents and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Platinum agents, Cisplatin and the tag pancreatic-deep-dive.
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Platinum agents, Cisplatin and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/